Natera, Inc. (NASDAQ:NTRA) is a prominent player in the medical research industry, specializing in genetic testing and diagnostics. The company is known for its innovative approach to non-invasive prenatal testing and oncology diagnostics. Natera competes with other companies in the genetic testing space, striving to maintain its position as a leader in the field.
On December 11, 2025, Cowen & Co. upgraded Natera's stock to a "Buy" rating, with the stock price at approximately $230.75. This upgrade reflects Cowen & Co.'s positive outlook on Natera, as highlighted in their report published by StreetInsider. The report, titled "Management Meetings Reflect Solid Momentum With Levers for Upside," suggests that Natera is well-positioned for growth. Baird Financial Group Inc. has shown confidence in Natera by significantly increasing its investment by 277.8% during the most recent quarter. According to their latest 13F filing with the SEC, Baird now holds 26,624 shares, having acquired an additional 19,576 shares. The total value of Baird's holdings in Natera is approximately $4.5 million, indicating strong institutional interest.
Other institutional investors have also adjusted their positions in Natera. Northwestern Mutual Wealth Management Co. increased its stake by 83.5% in the first quarter, now owning 233 shares valued at $33,000. Hilltop National Bank acquired a new stake in Natera during the same period, also valued at around $33,000. These moves suggest growing confidence in Natera's potential. Currently, Natera's stock price is $229.97, reflecting a decrease of 1.36% or $3.16. The stock has traded between $229.32 and $234.58 today. Over the past year, Natera's stock has reached a high of $246.90 and a low of $125.38. With a market capitalization of approximately $31.74 billion and a trading volume of 237,608 shares, Natera remains a significant player in the market.
